Potential DNA Vaccine for Haemorrhagic Septiceamia Disease

Chelliah, Shamini; Velappan, Rita Devi; Lim, Kang Tzin; Swee, Chuan Wei Kelvin; Rashid, Nurshamimi Nor; Rothan, Hussin A.; Kabir, Nurul; Ismail, Salmah

doi:10.1007/s12033-020-00244-0

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunizations with genomic expression libraries has emerged as a novel technology [ 41 , 42 ]. For identifying candidate vaccine genes that provide protection against pathogens, some studies have identified individual protective genes via the sequential fractionation of cDNA or genomic expression libraries [ 21 , 43 , 44 ]. The potential of OmpH gene as a vaccine candidate has been described and carried out in mice model against P. multocida .…”

Section: Discussionmentioning

confidence: 99%

“…The P. multocida toxin (PMT) DNA vaccine has the potential to protect infected animals from infections caused by P. multocida [ 18 ], while this DNA vaccine was able to provide protection against avian pasteurellosis by using two separate OMPs, OmpH and OmpA , and showed the highest degree of protection [ 19 , 20 ]. The pVAX1-ABA392 DNA vaccine is capable of producing a high titer of anti-HS antibodies caused by P. multocida and has the potential to be a vaccine candidate [ 21 ]. The aim of this study was therefore to characterize the nucleotide sequence of the OmpH gene using molecular genetics and bioinformatics techniques.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The immune response and protective efficacy of a potential DNA vaccine against virulent Pasteurella multocida

Yassein

Teleb

Hassan

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Pasteurella multocida is the main cause of several infections of farm animals, and the immunity gained from commercial vaccines is for the short term only and needs to be routinely administered, so work on new vaccines against virulent P. multocida is crucial. Results In this study, the OmpH gene was amplified from ten P. multocida strains, and the PCR products were sequenced and analyzed. The results of RFLP analysis of OmpH gene digested by MspI enzyme showed that all of ten strains examined possessed one restriction site and two fragments, 350 and 650 bp. The OmpH sequence of strain No. 10 was cloned into bacterial expression vector pUCP24, and the recombinant pUCP24-OmpH was expressed in E. coli DH5α. Serum samples obtained from the ELISA test from a group of vaccinated rats indicate that the antibodies were present at high titer in immunized rats and can be tested as a vaccine candidate with a challenge. Conclusions In rats infected with the DNA vaccine and inactivated vaccine, a significant increase in serum antibody levels was observed. In addition, the DNA vaccine provided the vaccinated rats with partial protection; however, the protective efficacy was greater than that offered by the live attenuated vaccine. This successful recombinant vaccine is immunogenic and may potentially be used as a vaccine in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The immune response and protective efficacy of a potential DNA vaccine against virulent Pasteurella multocida

Yassein

Teleb

Hassan

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Mouse models can play an important role in investigation of pathogenesis and vaccine development [317,[351][352][353][354][355][356][357][358][359][360][361][362][363]. Rats with or without immunosuppression have also been used to explore pathogenesis and novel vaccines [349][350][351][364][365][366]. Rabbits are occasionally used for vaccine evaluation and, along with mice, were recently used to evaluate a novel phage lysate marker vaccine along with a DIVA ELISA [358].…”

Section: Hemorrhagic Septicemiamentioning

confidence: 99%

Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences

Clemmons

Alfson

Dutton

2021

Animals

View full text Add to dashboard Cite

Animals provide food and other critical resources to most of the global population. As such, diseases of animals can cause dire consequences, especially disease with high rates of morbidity or mortality. Transboundary animal diseases (TADs) are highly contagious or transmissible, epidemic diseases, with the potential to spread rapidly across the globe and the potential to cause substantial socioeconomic and public health consequences. Transboundary animal diseases can threaten the global food supply, reduce the availability of non-food animal products, or cause the loss of human productivity or life. Further, TADs result in socioeconomic consequences from costs of control or preventative measures, and from trade restrictions. A greater understanding of the transmission, spread, and pathogenesis of these diseases is required. Further work is also needed to improve the efficacy and cost of both diagnostics and vaccines. This review aims to give a broad overview of 17 TADs, providing researchers and veterinarians with a current, succinct resource of salient details regarding these significant diseases. For each disease, we provide a synopsis of the disease and its status, species and geographic areas affected, a summary of in vitro or in vivo research models, and when available, information regarding prevention or treatment.

show abstract

Global commercialization and research of veterinary vaccines against Pasteurella multocida: 2015–2022 technological surveillance

Odio

Delgado

2023

Vet World

View full text Add to dashboard Cite

Background and Aim: Pasteurella multocida can infect a multitude of wild and domesticated animals, bacterial vaccines have become a crucial tool in combating antimicrobial resistance (AMR) in animal production. The study aimed to evaluate the current status and scientific trends related to veterinary vaccines against Pasteurella multocida during the 2015–2022 period. Materials and Methods: The characteristics of globally marketed vaccines were investigated based on the official websites of 22 pharmaceutical companies. VOSviewer® 1.6.18 was used to visualize networks of coauthorship and cooccurrence of keywords from papers published in English and available in Scopus. Results: Current commercial vaccines are mostly inactivated (81.7%), adjuvanted in aluminum hydroxide (57.8%), and designed to immunize cattle (33.0%). Investigational vaccines prioritize the inclusion of attenuated strains, peptide fragments, recombinant proteins, DNA as antigens, aluminum compounds as adjuvants and poultry as the target species. Conclusion: Despite advances in genetic engineering and biotechnology, there will be no changes in the commercial dominance of inactivated and aluminum hydroxide-adjuvanted vaccines in the short term (3–5 years). The future prospects for bacterial vaccines in animal production are promising, with advancements in vaccine formulation and genetic engineering, they have the potential to improve the sustainability of the industry. It is necessary to continue with the studies to improve the efficacy of the vaccines and their availability. Keywords: adjuvant, Pasteurella multocida, strain, technological surveillance, vaccine.

show abstract

Potential DNA Vaccine for Haemorrhagic Septiceamia Disease

Cited by 5 publications

References 23 publications

The immune response and protective efficacy of a potential DNA vaccine against virulent Pasteurella multocida

The immune response and protective efficacy of a potential DNA vaccine against virulent Pasteurella multocida

Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences

Global commercialization and research of veterinary vaccines against Pasteurella multocida: 2015–2022 technological surveillance

Contact Info

Product

Resources

About